Interleukin-6 Mediates Resistance to PI3K-pathway–targeted Therapy in Lymphoma
BMC Cancer - United Kingdom
doi 10.1186/s12885-019-6057-7
Full Text
Open PDFAbstract
Available in full text
Date
October 10, 2019
Authors
Publisher
Springer Science and Business Media LLC